Finpecia

Legal status and availability in the UK

Finasteride is a prescription-only medicine (POM) in the UK. Finpecia is not licensed in the UK.

In our online pharmacy, Finpecia is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Finpecia information

• INN (international nonproprietary name): Finasteride
• Brand names available in the United Kingdom: Propecia (Merck) and Proscar (Merck) are licensed in the UK; generic finasteride tablets are available. Finpecia is not a UK-licensed brand.
• ATC code: D11AX10 (alopecia); G04CB01 (BPH)
• Forms and dosages: 1 mg tablets for male pattern hair loss; 5 mg tablets for benign prostatic hyperplasia
• Registration status in the United Kingdom: Finpecia is not licensed in the UK; finasteride is licensed by the MHRA as Propecia 1 mg and Proscar 5 mg, with generics available; prescription only
• OTC / Rx classification: Prescription-only medicine (POM)

What Finpecia is — active ingredient and classification

INN, ATC codes and legal status

What exactly is in a Finpecia tablet and how is it classified?

Finpecia contains the INN finasteride, a 5α‑reductase inhibitor used for androgenetic alopecia and BPH.

The ATC code for finasteride when used in hair loss is D11AX10 and for BPH is G04CB01.

Finasteride is a prescription-only medicine (POM) in the UK, and the MHRA has licensed Propecia 1 mg and Proscar 5 mg.

The product is typically supplied as 1 mg tablets for male pattern hair loss and 5 mg tablets for BPH.

Finasteride is not for use in women and children.

• INN: Finasteride
• ATC: D11AX10 (alopecia); G04CB01 (BPH)
• Status: Prescription-only medicine (POM)

Indications — alopecia vs BPH and off‑label use

Licensed uses and non‑recommended populations

Who should take Finpecia and who should not?

Finasteride 1 mg (Finpecia/Propecia) is licensed for male pattern hair loss in adult men.

Finasteride 5 mg (Proscar) is licensed for benign prostatic hyperplasia and is used at a higher daily dose.

Finasteride is not approved for women or children and is contraindicated in pregnancy due to risk to a male foetus.

Off‑label uses such as topical combinations or specialist transgender care may be considered under specialist supervision and documentation.

Pharmacists must verify the indication, confirm a valid prescription and provide risk counselling before dispensing.

Dosage, administration and dispensing guidance

Typical regimens, missed dose and overdose handling

How should finasteride be taken?

The standard dose for hair loss is 1 mg orally once daily and for BPH is 5 mg once daily.

Tablets are swallowed whole at the same time each day and should not be crushed or split because of exposure risks to pregnant women.

If a patient misses a dose they should take it as soon as they remember within the same day and should not double the next dose.

In overdose there is no specific antidote; treatment is symptomatic and supportive with clinical observation.

Tablet strengths and typical pack sizes

• 1 mg — typically 28 or 30 tablets (Propecia).
• 5 mg — typically 28–30 tablets (Proscar).

Onset of action, treatment duration and expected outcomes

Timeline for visible effect and maintenance therapy

When will you see a difference and how long must treatment continue?

Clinical and real‑world timelines show stabilisation of hair loss commonly by three months, with visible regrowth often by six to twelve months.

For BPH, symptomatic improvement may require a minimum of six months of treatment before full effect is evident.

Benefits are maintained only with ongoing therapy and stopping finasteride usually leads to loss of gains over six to twelve months.

Younger men and those with recent thinning tend to respond better in terms of density improvement.

• 3 Months: Stabilisation of hair loss for many patients.
• 6 Months: Early regrowth in some patients.
• 12 Months: More noticeable regrowth; continued dosing required to keep results.

Safety profile — contraindications and high‑risk groups

Absolute contraindications and precautions

What are the absolute no‑go situations for finasteride?

Finasteride is absolutely contraindicated in pregnancy and must not be used by women who are or may become pregnant because it is teratogenic to male foetuses.

It is also not indicated for children and should not be given to those under 18 years.

Known hypersensitivity to finasteride or any excipients is an absolute contraindication.

Relative cautions include significant hepatic impairment and those with prior allergic reactions; careful monitoring is advised in obstructive uropathy.

• Contraindications: pregnancy, women/children, known hypersensitivity.

Patients should be told about the handling warnings for tablets and should store medicines away from children.

Side effects, incidence and post‑finasteride syndrome

Common, uncommon and debated long‑term effects

How common are sexual side effects and what about long‑term reports?

Common adverse effects include reduced libido, erectile dysfunction and ejaculatory disorders.

Less common effects reported include testicular pain, breast changes such as gynaecomastia and mood changes.

Most sexual side effects resolve after stopping finasteride, but a subset of patients report persistent symptoms described as post‑finasteride syndrome; this remains under investigation.

For men being treated for BPH, finasteride can lower PSA levels which should be taken into account in prostate monitoring.

Frequently asked questions

• Q: Will sexual side effects definitely occur? A: No; they are reported but not guaranteed and most resolve on stopping treatment.
• Q: What is post‑finasteride syndrome? A: Persistent symptoms have been reported and are the subject of ongoing research; report concerns promptly.

Drug interactions and laboratory considerations

Common co‑medications and monitoring implications

Are there medicines or tests that need special attention while on finasteride?

Finasteride has a low propensity for pharmacokinetic drug interactions but is metabolised hepatically, so caution with other hepatically metabolised drugs is prudent.

Finasteride reduces PSA levels over time — approximately a 50% reduction may occur — and clinicians must interpret PSA results with this effect in mind.

Concurrent use with other 5α‑reductase inhibitors such as dutasteride is generally avoided and should prompt prescriber discussion.

No routine renal dose adjustment is required for mild to moderate impairment, but caution in severe renal dysfunction is reasonable.

Monitoring, follow‑up and when to refer

Checks and red flags for GP/urology referral

What checks can pharmacists perform and when should you refer back to a GP or urologist?

Pharmacists should confirm ongoing indication, review side effects especially sexual or mood changes, and check adherence at routine intervals.

Recommended follow‑up includes checks around three months and again at 12 months, or earlier if concerns arise.

Red flags prompting urgent referral include persistent sexual dysfunction after stopping the drug, breast lumps or discharge, severe mood changes or signs of liver dysfunction.

For BPH patients ensure coordinated PSA monitoring and refer urgently for acute urinary retention.

• Suggested follow‑up schedule: baseline counselling, 3‑month side‑effect check, 12‑month comprehensive review.

Comparing brands and generics — Finpecia vs Propecia vs others

Bioequivalence and packaging

Does choosing a generic like Finpecia change how the medicine works?

Finpecia (Cipla) is a generic 1 mg finasteride product that is not licensed in the UK, while Propecia (Merck) is the original branded formulation.

Licensed generic finasteride tablets are available in the UK and are considered bioequivalent.

Packing, excipients and blister sizes differ between brands and generics.

Storage, handling and dispensing safety

Patient instructions

How should finasteride be stored?

Store finasteride below 30°C in the original packaging, away from moisture and light.

Tablets should not be split or crushed to avoid inadvertent exposure to pregnant women who could handle residues.

Handling warnings for pregnant women apply, and medicines should be kept out of reach of children.

• Home storage points: original blister, cool dry place, out of direct sunlight, out of reach of children.

Alternatives and combination options (dutasteride, minoxidil)

When to consider switching or combining therapies

What are common alternatives or add‑ons to finasteride for hair loss?

Topical minoxidil is a licensed alternative for hair loss and is often used in combination with oral finasteride for improved results.

Dutasteride is a more potent 5α‑reductase inhibitor that is licensed for BPH and used off‑label for hair loss in some settings.

Combination therapy should be discussed with the prescriber because dutasteride may increase efficacy but also changes the safety profile.

Herbal supplements such as saw palmetto are used by some patients but lack the regulatory approval and robust evidence of licensed medicines.

Practical FAQ and patient counselling tips

Common questions

How long until I see results? Expect three to twelve months for effect and ongoing treatment to maintain gains.

Can women take it? No — finasteride is contraindicated in women who are or may become pregnant.

What if I miss a dose? Take it the same day when remembered and do not double the next dose.

Do men need to avoid fathering children? Men taking finasteride do not need to avoid fathering children, but any concerns should be discussed with the prescriber.

Report adverse events via the MHRA Yellow Card scheme and seek urgent care for breast lumps, severe mood changes or other red‑flag symptoms.

Delivery across the United Kingdom